L. Roy Papp & Associates’s Lucira Health, Inc. Common Stock LHDX Stock Holding History

L. Roy Papp & Associates’s Portfolio LHDX Stock Details LHDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-150,699	Closed	-$16.7K	–	170
2022 Q4	$16.7K	Buy	150,699 +36,205	+32%	+$23.1K	﹤0.01%	166
2022 Q3	$121K	Sell	114,494 -10,000	-8%	-$22.8K	0.02%	161
2022 Q2	$232K	Buy	124,494 +16,489	+15%	+$40.1K	0.03%	158
2022 Q1	$386K	Buy	108,005 +62,505	+137%	+$307K	0.05%	140
2021 Q4	$392K	Sell	45,500 -350	-0.8%	-$2.23K	0.04%	146
2021 Q3	$348K	Buy	+45,850	New	+$387K	0.04%	149
2021 Q2	–	Sell	-45,350	Closed	-$549K	–	177
2021 Q1	$549K	Buy	+45,350	New	+$900K	0.08%	118

Other funds holding LHDX

Eclipse Ventures Palo Alto, California $2.57B AUM

Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Resolute Advisors San Francisco, California $417M AUM 60.99% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

L. Roy Papp & Associates's LHDX Position: Q1 2023 in Review

L. Roy Papp & Associates sold out of Lucira Health, Inc. Common Stock (LHDX) in Q1 2023, closing a stake of 150,699 shares — an estimated $16.7K sold.

L. Roy Papp & Associates first reported a position in LHDX in Q1 2021 and held it in 7 quarters. The position peaked at $549K in Q1 2021. 6 funds tracked by Wall St. Rank hold LHDX as of Q1 2023.

L. Roy Papp & Associates reported no remaining Lucira Health, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
L. Roy Papp & Associates sold 150,699 Lucira Health, Inc. Common Stock shares in Q1 2023, an estimated $16.7K.
L. Roy Papp & Associates first reported a position in Lucira Health, Inc. Common Stock in Q1 2021 and held it in 7 quarters.
L. Roy Papp & Associates's Lucira Health, Inc. Common Stock position peaked at $549K in Q1 2021.
6 funds tracked by Wall St. Rank held Lucira Health, Inc. Common Stock as of Q1 2023.

Based on L. Roy Papp & Associates's 13F filing for Q1 2023, filed 5 May 2023.